{"name":"Ensho Therapeutics, Inc.","slug":"ensho-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Ensho Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with significant unmet medical needs. The company's lead candidate, NSHO-101, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQaGhqWDAyY2tLbEhXRmlZZGp2ZjlIMjJmTWJ1QnE5QkhDZUtfZ0hYZXpnQmk3ajJhX0pnd0JEMXBKQklPcEpiODI4cFVmdkFodlBiX29VYXlPclJwM2tQZ1ZtLVdIalQydGQwSU5xTjRLbUpNdEdhM0FjdEMxOFhJcXhWZ1k4c3d2REREcjlJb083QTlYWXZyYkxzelYtYWZLYS1kY09feWpQY3Vjbi1F?oc=5","date":"2025-11-19","type":"pipeline","source":"BioSpace","summary":"Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions - BioSpace","headline":"Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBYTzBtQm9xMUJGZ3RQZ2gtUGdPR1BxWHZzbXNWNTRLMWlnRVh1U0VQYUVteUFzdElxU3VzM0t4eXFqLThlVmFzcFpKRkpMZFVjUlFkM2ZaR3hXNHNPNlFKUUEya0VaQTZlSi1CVENn?oc=5","date":"2025-02-24","type":"trial","source":"Clinical Trials Arena","summary":"Ensho Therapeutics reveals data of NSHO-101 for inflammatory bowel disease - Clinical Trials Arena","headline":"Ensho Therapeutics reveals data of NSHO-101 for inflammatory bowel disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gJBVV95cUxNc1c5ZllXeGZnNlVLNERSaFRPYUNINVI0XzVWZXFmMFlNQlQ4QzNXTmJnUVNHNnc0cUgtOTl4aW5hUi1RUlR6bV8wZHNob2JGTHJ6aWpORkVKTkMwdFNvM1JRRF9UaWxVNW1VN21UYkMtZHhsZVk4amp5R2JVSUwySG8ybHN6OTlheXhnb0x1SlV6MXlocnFpUEdFemNjR3JSSVc3dkhYYnZsR2hSOUhtbmI3U1J6MmtveWFha0RmVzZWcWhNMXhVLW5rYkxQN25JQWFCRFRzbzJ1NzJNSVN3eXZTQmZkRDZFN01LWEFKZTFtMWxQdDA3QkJCNUZ0UVp0UGRUMG9HUXl1RGlwYm5NLTZ6bHNuN2JDUEhKSzBPc0RUMXRmNVpDUm5ELU16UFFlclZTSEY3T0J2RTBsY3hVRk1DNFRnbUQwRFFwOE1lNWhsUjVTNVJwOEkxZTl1Zw?oc=5","date":"2025-02-21","type":"trial","source":"GlobeNewswire","summary":"Ensho Therapeutics Announces Presentation of Data - GlobeNewswire","headline":"Ensho Therapeutics Announces Presentation of Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOYTZ6QmJnYnJ5YmYzTG9uVnp1SWJqTVU2VmF6RDB4M25SVHJRdEdKd0JrUWk2dUNUNFE0MXcwQkt0NHpjcy15UEZXT29QTGU5YWl5a2RsMWRPWURZZnJ2MGZJc1Jodkt3SldjVy1YU0k0dUYwQUFwY20yZlhkSWNtcmZWUVlwOTNhYUFjNE0tZTRhY0liNnRub0dDYVg?oc=5","date":"2025-02-14","type":"trial","source":"Yahoo Finance","summary":"Ensho Therapeutics Announces Upcoming Presentation at ECCO 2025 of Phase 1, Once-Daily Dosing Data for NSHO-101, an Oral α4β7 Inhibitor for Inflammatory Bowel Disease - Yahoo Finance","headline":"Ensho Therapeutics Announces Upcoming Presentation at ECCO 2025 of Phase 1, Once-Daily Dosing Data for NSHO-101, an Oral","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxORGtKQjgtZzh6c01UWDNqM2hjRkM2X1NLYlUxRVQ0aGw1Q1JDcDlrTEpyMUxqQ3Q5ZUxvVzRVbWZrZk90bVJieEJOUnpCaU96aFZPR19yeS1vdTVPa282dHJPU01JdHl0N05ld1JoNXBsZVVvdFZ6R0JtaEtsMlZ6NzI0bjBSMFNjVF9QbnAzajU3U3g3U003V0ZEcWtYQmltbUYtNkhLVQ?oc=5","date":"2024-07-30","type":"pipeline","source":"BioWorld News","summary":"Ensho debuts to target gut inflammation with oral α4β7 inhibitors - BioWorld News","headline":"Ensho debuts to target gut inflammation with oral α4β7 inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNcDhaSi1Gd05Xdk11OGppZjM5WXplbVRlclA0bi14WVVJa2hPcDRmazItZm5sSG1JRTlidUMwOUpzVjNob1JhRFJRUlJUYVN3djVlelkwaVdqMld1cW1ncW00SUVMNmZoODNJTnhMMXFnOUNicHlXUkpfS3ZicUdGeXdxb2QwMHk4Sk52Rg?oc=5","date":"2024-07-17","type":"pipeline","source":"Pharma Voice","summary":"A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill - Pharma Voice","headline":"A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPbWNIbVI1bVFjX0hBNzlrVVlEbGU2Smk5VkFKMG53c25iSllxQjFybEh4LVNScTlja1RIYlJxT3BhZFFmbjNyWmxzQy1DcVNzSWpUcml1RnA4Sldpc0RCd0xyLUIwWExZdWE5T1JLWml0RzhrTzVkaDhTZFBWRXI1SHdfYS1DekQ1ajBmYXRVTk9CaWd6akt0VUpqelFhSXZocmhveGtzZk9TQ3dHNlRRNw?oc=5","date":"2024-07-12","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Pfizer's Mikael Dolsten steps down as AbbVie's R&D org switches leaders - Fierce Biotech","headline":"Chutes & Ladders—Pfizer's Mikael Dolsten steps down as AbbVie's R&D org switches leaders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOa3BxeHB5bFE4OHFYenNmQndnTTRXQXlfZXNjNDg4bVNhRWdQYVlvcWRjM0dhcDVyMTFseUhsZVpMQ2t0cHpwVWw4cGs5b2hoSGJWRjdOeU9tTWgzc2N4THl0Q05zeHctVzJ6WG01YlZtekNvU1RCdjQwaDdKTnRUNWNnbVI0NGxtN21oTkxQd1d5UktOMGFjWl9OVllsOTJ2Qzd6eWdUZG1ITlRqVzgyNm12NmhkU18wdk5oX2pEeTE?oc=5","date":"2024-06-28","type":"pipeline","source":"Fierce Biotech","summary":"Ensho emerges with inflammatory disease portfolio from Eisai's EA Pharma - Fierce Biotech","headline":"Ensho emerges with inflammatory disease portfolio from Eisai's EA Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPYU1ybTRWSGVHVDNFY0plOVZXQ19EbG94Y3ZsT0Y0alRCNEpNaHQxcGdpUkpFallKS2VOREJpSDNNSnZ2VVlGR0FoRURRWTVoVVlGZm11Vl82VlYxS3JHQmU2c0cyaXM4Xy1DS0RWUGI2NXZORlM3cjdKd3hza1VwRVBjU19SX3kzZlMxMFVmcW1LcmMzcGZEU1FDUTNMNzQ3cloyWFJNTl9vWXMxemtiNVJwRXRHc3RMU0ZnTUd3UFgyTFgzUTBMOHpBSnJQejFWZW9PMkRvWUwwcXljWWxPREFWbVpKT2V6RGVTUEFibzRrWUdSbFRVY0ItNjMweGl3LXpLMHVQRV9PU1E?oc=5","date":"2024-06-27","type":"trial","source":"GlobeNewswire","summary":"Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease - GlobeNewswire","headline":"Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}